REGIONAL AND INTRAREGIONAL CLUSTERS NOVUM RESEARCH PARK 1972Huddinge University Hospital 1985-91Novum Research Foundations Center for Biotechnology.

En presentation över ämnet: "REGIONAL AND INTRAREGIONAL CLUSTERS NOVUM RESEARCH PARK 1972Huddinge University Hospital 1985-91Novum Research Foundations Center for Biotechnology."— Presentationens avskrift:

1

2 REGIONAL AND INTRAREGIONAL CLUSTERS

3

4 NOVUM RESEARCH PARK 1972Huddinge University Hospital 1985-91Novum Research Foundations Center for Biotechnology Center for Nutrition & Toxicology Center for Structural Biochemistry Center for Oral Biology Founders: Stockholm County Council & Karolinska Institute Purpose: To create a biomedical center of excellence 1985 - R&D companies in and near Novum. Expanison of research Improvements of infrastructure (communications, hotel, shops) 1989Novum Research Center 1997 - 02University of Södertörn 2000 -Planning for Novum BioCity

5 NOVUM RESEARCH PARK A.D. 2002 A qualified environment for front-line research and for the establishment and growth of research-based companies Novum Research Foundations (4 foundations ~ 350 employees) biomedical basic research Departments & Centers of Research (~ 350 employees) Karolinska Institute, Huddinge University Hospital, Södertörn University biomedical & medical technology research Research Companies (20 companies, ~ 450 employees) Novum Business Development Group business counselling, strategic planning information & visitor’s service

6 NOVUM PRECLINICAL RESEARCH Nuclear receptors Signal transduction Molecular genetics Molecular nutrition Molecular immunology Structural biochemistry

7 NOVUM CLINICAL RESEARCH Cancer Osteoporosis Metabolic disorders Alzheimer’s disease Cellular therapy Virus infection (Hepatitis) Gene therapy

8 NEIGHBOURS AND PARTNERS IN NOVUM RESEARCH PARK HUDDINGE UNIVERSITY HOSPITAL THE KAROLINSKA INSTITUTET MEDICAL SCHOOL SÖDERTÖRN UNIVERSITY COLLEGE SERVICE COMPANIES (about 25) _______________________ Appr. 17.000 personer (employees & students) working daily in the park area

9 BUSINESS COUNSELLING IN NOVUM Patenting Licensing Business law Market analysis Business Planning Financing

10 NOVUM’S RESEARCH COMPANIES Multinationals AstraZenecaPain Control Research Baxter MedicalRenal Function Research Sumitomo Pharmaceuticals Alzheimer’s disease

11 Novum’s Research Companies R&D specialists Karo BioReceptorbiology MedivirHIV & Herpes antivirals TripepHIV antivirals LightUp TechnologiesDNA probe technology/diagnostics AvarisGenevector technolog OxypharmaRheumatoid Arthritis

12 NOVUM’S RESEARCH COMPANIES Service & Technology providers CyberGeneSequencing, genetic diagnostics Nova Snitt AnalysisHistology SciBaseImpedance analysis of skin & mucosa Innomed-Konsult Design of GMP facilities

13

14 NOVUM BIOCITY

15

16 NOVUM RESEARCH PARK

17 Nuclear Receptors Large family of receptorsImportant drugs on the market Validated drug targetsBind hormones with high affinity New technology and receptors offer improved treatments and new indications Target gene Nuclear Receptor Hormones or Metabolic Intermediates Protein Changed Cell Function

18 LXR New Promising Target for Atherosclerosis Upregulates cholesterol pump (ABCA1) Upregulates APO-E in macrophages Upregulates 7- hydroxylase (cholesterol break down)

19 LXR Concept to Treat Atherosclerosis LXR stimulates synthesis of ABC1 protein Drug compound stimulates LXR activity LXR ABC1-protein + Cell Atherosclerosis Tangier disease; non-functional ABC-1 leads to atherosclerosis Treated blood vessel ABC1 removes harmful cholesterol

20 Karo Bio – Leader in Nuclear Receptor and Proteomics-Based Drug Discovery

21 Karo Bio AB Stockholm Karo Bio USA, Inc. Durham, NC Karo Bio, Inc. San Francisco Bayer AG GPC Biotech NovImmune S.A. Serono International Aventis Boehringer Ingelheim BMSMerckAHPAbbott

22  Develop pharmaceuticals for major markets  Be a leading company within the field of nuclear receptors and proteomics-based drug discovery  Conduct clinical development and marketing through partners and licensees  Finance operations through partnerships Business Concept

23 Revenue Model of Karo Bio DrugdiscoveryPre-clinicaldevelopmentClinicaldevelopmentMarket Royalty on sales Targetidentification Up-front payment Research funding R&D milestones

24 Strategic Position Scientific network Partners KARO BIO Karolinska Insitutet UCSF Duke University University of Bochum Sahlgrenska Hospital University of York … Abbott Laboratories Bristol-Myers Squibb Merck & Co, Inc. Aventis…

25 Nuclear Receptor Project Portfolio Drug discovery Preclinical Development Phase IPhase IIPhase IIINDA Target and indication validation THR Cardiac arrhythmia /KB ER Merck THR Obesity BMS THR 015/Cardiac arrhythmia/KB THR KB2611/ Skin atrophy /KB THR Glaucoma/KB GR Diabetes Abbott 1 21 2 Anti-microbials/KB LXR AHP AR Prostate cancer /KB MR Heart failure /KB GR Inflammation /KB …...C l i n i c a l D e v e l o p m e n t…...

26 Karo Bio has a diverse nuclear receptor research portfolio Drug discovery Preclinical development Phase IPhase IIPhase III NDA/ Market Disease area Clinical development Oestrogen receptor Type II diabetes Obesity Athero- sclerosis Karo Bio has four profitable nuclear receptor collaborations in potential block-buster areas 80 MUSD + Royalties 56 MUSD + Royalties 40 MUSD + Royalties 100 MUSD + Royalties

27 Några reflektioner kring ett nytt paradigm för medicinsk och bioteknisk forskning Avståndet mellan laboratoriebänken och patientens säng har minskat betydligt och minskar allt snabbare i takt med den nya molekylärbiologiska forskningens landvinningar Enda sättet att föra över forskningsresultat från lab.bänken till patienten går via patentering och kommersialisering Den nutida laboratorieforskaren har ett etiskt imperativ att börja arbeta i denna riktning (modern tillämpning av den Hippokratiska eden!)

28 Några reflektioner…… (forts.) Det nya paradigmet för medicinsk/naturvetenskaplig forskning består i en trestegsraket, akademi, SMEs samt stora företag, där de två första stegen bör samlokaliseras under ett tak I detta cluster kommer nya forskningsstrategier och forskningstekniker att växa fram samtidigt som nya utbildningslinjer med kombinationer av bioteknik, medicin, ekonomi, juridik, etik mm kommer att utvecklas Allt detta betyder effektivare forskning, större konkurrenskraft i ett internationellt perspektiv samt bättre ekonomi för Sverige